Trial watch: Phase II failures: 2008–2010

By J. Arrowsmith. Nature reviews. Drug discovery, 2011

595 citations recorded by the source corpus.

Subfields: Civil and Structural Engineering, Safety, Risk, Reliability and Quality, Statistics and Probability

View Paper: https://www.semanticscholar.org/paper/4135f05737d0d75c766325481242753309d26b81

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Civil and Structural Engineering

1. David E. Shaw
2. David W. Borhani

In Safety, Risk, Reliability and Quality

1. David E. Shaw
2. David W. Borhani

In Statistics and Probability

1. David E. Shaw
2. David W. Borhani

Citations in the corpus

• Toxicity Testing in the 21st Century Beyond Environmental Chemicals (2015, result): “Recent reports, including one from AstraZeneca, indicate that this trend has not changed over the last decade (Arrowsmith, 2011; Arrowsmith and Miller, 2013; Cook et al., 2014).”
• The future of molecular dynamics simulations in drug discovery (2011, background): “[11] Two-thirds of recent Phase III failures are due to inadequate efficacy [12], as are more than half of Phase II [13] and * 16% of Phase I [14] failures.”